{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:47:32Z","timestamp":1761554852656,"version":"build-2065373602"},"reference-count":96,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hfc.2023.12.010","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T15:32:49Z","timestamp":1709911969000},"page":"209-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pulmonary Hypertension in Adult Congenital Heart Disease\u2013Related Heart Failure"],"prefix":"10.1016","volume":"20","author":[{"given":"Jonathan","family":"Kusner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Krasuski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0735-1097(01)01272-4","article-title":"Task force 1: the changing profile of congenital heart disease in adult life","volume":"37","author":"Warnes","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.hfc.2023.12.010_bib2","first-page":"1233","article-title":"Risk factors for excess mortality in adults with congenital heart diseases","volume":"38","author":"Oliver","year":"2017","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.hfc.2023.12.010_bib3","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/eurheartj\/ehq032","article-title":"Mortality in adult congenital heart disease","volume":"31","author":"Verheugt","year":"2010","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.hfc.2023.12.010_bib4","first-page":"1","article-title":"Management of cardiovascular risk factors in adults with congenital heart disease","volume":"3","author":"Lui","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jacc.2011.03.033","article-title":"Diagnosis of pulmonary hypertension in the congenital heart disease adult population: Impact on outcomes","volume":"58","author":"Lowe","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2023.12.010_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.hfc.2023.12.010_bib7","first-page":"1","article-title":"2022 ESC\/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension Developed by the Task Force for the Diagnosis and Treatment of (ESC) and the European Respiratory Society (ERS)","volume":"00","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10741-019-09847-5","article-title":"Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management","volume":"25","author":"Papamichalis","year":"2020","journal-title":"Heart Fail Rev"},{"issue":"4","key":"10.1016\/j.hfc.2023.12.010_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/01.CIR.0000153798.78540.87","article-title":"Transforming growth factor-\u03b2 receptor mutations and pulmonary arterial hypertension in childhood","volume":"111","author":"Harrison","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2023.12.010_bib10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/CIRCULATIONAHA.105.592386","article-title":"Pulmonary vascular disease in adults with congenital heart disease","volume":"115","author":"Diller","year":"2007","journal-title":"Circulation"},{"issue":"4 Part 1","key":"10.1016\/j.hfc.2023.12.010_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/01.CIR.18.4.533","article-title":"The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects","volume":"18","author":"HEATH","year":"1958","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hfc.2023.12.010_bib12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1161\/01.CIR.58.6.1107","article-title":"Lung biopsy in congenital heart disease: A morphometric approach to pulmonary vascular disease","volume":"58","author":"Rabinovitch","year":"1978","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hfc.2023.12.010_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/heart.88.6.658","article-title":"Pulmonary hypertension in the young","volume":"88","author":"Haworth","year":"2002","journal-title":"Heart"},{"issue":"1 14\u20131","key":"10.1016\/j.hfc.2023.12.010_bib14","article-title":"Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats","volume":"270","author":"Zamora","year":"1996","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"10.1016\/j.hfc.2023.12.010_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/heartjnl-2018-314025","article-title":"Assessment of reversibility in pulmonary arterial hypertension and congenital heart disease","volume":"105","author":"Van Der Feen","year":"2019","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/01.CIR.76.5.1037","article-title":"Isolated atrial septal defect with pulmonary vascular obstructive disease - long-term follow-up and prediction of outcome after surgical correction","volume":"76","author":"Steele","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2023.12.010_bib17","doi-asserted-by":"crossref","first-page":"II42","DOI":"10.1136\/heartjnl-2015-308378","volume":"102","author":"Kozlik-Feldmann","year":"2016","journal-title":"Heart"},{"issue":"15","key":"10.1016\/j.hfc.2023.12.010_bib18","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/CIRCULATIONAHA.116.023033","article-title":"Predictors of Death in Contemporary Adult Patients with Eisenmenger Syndrome: A Multicenter Study","volume":"135","author":"Kempny","year":"2017","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2023.12.010_bib19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.111.085761","article-title":"Pulmonary hypertension due to left heart disease","volume":"126","author":"Guazzi","year":"2012","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.hfc.2023.12.010_bib20","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCRESAHA.121.319970","article-title":"Group 3 Pulmonary Hypertension: From Bench to Bedside","volume":"130","author":"Singh","year":"2022","journal-title":"Circ Res"},{"issue":"16","key":"10.1016\/j.hfc.2023.12.010_bib21","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1161\/CIRCULATIONAHA.105.602565","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"113","author":"Hoeper","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2023.12.010_bib22","doi-asserted-by":"crossref","unstructured":"Morgenstern I, Kauczor H. Bronchopulmonary Shunts in Thromboembolic Pulmonary Hypertension: Evaluation with Helical. 2002;(November):1209-1215.","DOI":"10.2214\/ajr.179.5.1791209"},{"issue":"2","key":"10.1016\/j.hfc.2023.12.010_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/hrt.78.2.171","article-title":"Comparison of bronchopulmonary collaterals and collateral blood flow in patients with chronic thromboembolic and primary pulmonary hypertension","volume":"78","author":"Endrys","year":"1997","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.hfc.2023.12.010_bib24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/thx.37.12.893","article-title":"Pulmonary vascular and alveolar development in tetralogy of Fallot: A recommendation for early correction","volume":"37","author":"Johnson","year":"1982","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.hfc.2023.12.010_bib25","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/thx.32.2.129","article-title":"Quantitative structural study of pulmonary circulation in the newborn with pulmonary atresia","volume":"32","author":"Haworth","year":"1977","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.hfc.2023.12.010_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1183\/09031936.05.00015405","article-title":"The role of increased pulmonary blood flow in pulmonary arterial hypertension","volume":"26","author":"van Albada","year":"2005","journal-title":"Eur Respir J"},{"issue":"5099","key":"10.1016\/j.hfc.2023.12.010_bib27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/bmj.2.5099.755","article-title":"The Eisenmenger Syndrome or Pulmonary Hypertension with Reversed Central Shunt","volume":"2","author":"Wood","year":"1958","journal-title":"Br Med J"},{"issue":"6","key":"10.1016\/j.hfc.2023.12.010_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/0002-9149(71)90054-3","article-title":"Fate of the patient with the Eisenmenger syndrome","volume":"28","author":"Young","year":"1971","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2023.12.010_bib29","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijcard.2006.09.017","article-title":"Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registry","volume":"120","author":"Duffels","year":"2007","journal-title":"Int J Cardiol"},{"issue":"25 SUPPL","key":"10.1016\/j.hfc.2023.12.010_bib30","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hfc.2023.12.010_bib31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijcard.2019.12.070","article-title":"Pulmonary hypertension after shunt closure in patients with simple congenital heart defects","volume":"308","author":"Lammers","year":"2020","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2023.12.010_bib32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5606\/tgkdc.dergisi.2022.23639","article-title":"Predictors of pulmonary hypertension after atrial septal defect closure: Impact of atrial fibrillation","volume":"30","author":"\u00c7elik","year":"2022","journal-title":"Turkish J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.hfc.2023.12.010_bib33","doi-asserted-by":"crossref","unstructured":"Stout KK, Daniels CJ, Aboulhosn JA, et\u00a0al. 2018 AHA\/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Vol 139.; 2019. doi:10.1161\/CIR.0000000000000603.","DOI":"10.1161\/CIR.0000000000000683"},{"issue":"11","key":"10.1016\/j.hfc.2023.12.010_bib34","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurheartj\/eht072","article-title":"Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: A comparison between clinical subgroups","volume":"35","author":"Manes","year":"2014","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.hfc.2023.12.010_bib35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","volume":"23","author":"Rudski","year":"2010","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"9","key":"10.1016\/j.hfc.2023.12.010_bib36","doi-asserted-by":"crossref","first-page":"100649","DOI":"10.1016\/j.jacadv.2023.100649","article-title":"Timely PAH Identification in Adults With Repaired Congenital Heart Disease? The ACHD-QuERI Registry Insights","volume":"2","author":"Landzberg","year":"2023","journal-title":"JACC Adv"},{"issue":"4","key":"10.1016\/j.hfc.2023.12.010_bib37","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/chd.12481","article-title":"Arrhythmia burden and related outcomes in Eisenmenger syndrome","volume":"12","author":"Baskar","year":"2017","journal-title":"Congenit Heart Dis"},{"issue":"2","key":"10.1016\/j.hfc.2023.12.010_bib38","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/j.thromres.2013.07.006","article-title":"High haematocrit in cyanotic congenital heart disease affects how fibrinogen activity is determined by rotational thromboelastometry","volume":"132","author":"Westbury","year":"2013","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib39","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/j.ijcard.2012.06.019","article-title":"Fibrinogen function is impaired in whole blood from patients with cyanotic congenital heart disease","volume":"167","author":"Jensen","year":"2013","journal-title":"Int J Cardiol"},{"issue":"14","key":"10.1016\/j.hfc.2023.12.010_bib40","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/eurheartj\/ehl116","article-title":"Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: A combined retrospective and case-control study","volume":"27","author":"Diller","year":"2006","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.hfc.2023.12.010_bib41","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1161\/CIRCULATIONAHA.107.734921","article-title":"Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease","volume":"117","author":"Dimopoulos","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2023.12.010_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/heart.84.1.53","article-title":"Haemodynamic correlates and prognostic significance of serum uric acid in adult patients with Eisenmenger syndrome","volume":"84","author":"Oya","year":"2000","journal-title":"Heart"},{"issue":"6","key":"10.1016\/j.hfc.2023.12.010_bib43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/eurheartj\/ehaa554","article-title":"2020 ESC Guidelines for the management of adult congenital heart disease","volume":"42","author":"Baumgartner","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2023.12.010_bib44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Gali\u00e8","year":"2006","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.hfc.2023.12.010_bib45","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2023.12.010_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCULATIONAHA.118.033575","article-title":"Evaluation of Macitentan in Patients with Eisenmenger Syndrome: Results from the Randomized, Controlled MAESTRO Study","volume":"139","author":"Gatzoulis","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1747-0803.2011.00561.x","article-title":"Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger Syndrome\u2014A randomized, placebo-controlled, double-blind crossover study","volume":"6","author":"Mukhopadhyay","year":"2011","journal-title":"Congenit Heart Dis"},{"issue":"4","key":"10.1016\/j.hfc.2023.12.010_bib48","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.ahj.2005.09.006","article-title":"A\u00a0randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension","volume":"151","author":"Singh","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.hfc.2023.12.010_bib49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijcard.2019.07.004","article-title":"A\u00a0single-centre, placebo-controlled, double-blind randomised cross-over study of nebulised iloprost in patients with Eisenmenger syndrome: A pilot study","volume":"299","author":"Nashat","year":"2020","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2023.12.010_bib50","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/eurheartj\/ehr461","article-title":"Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily lifesingle centre experience and review of published data","volume":"33","author":"Kempny","year":"2012","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.hfc.2023.12.010_bib51","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo-controlled, double-blinded trial","volume":"31","author":"Iversen","year":"2010","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.hfc.2023.12.010_bib52","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.hfc.2023.12.010_bib53","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.hfc.2023.12.010_bib54","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib55","first-page":"2","article-title":"The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome","volume":"54","author":"D\u2019Alto","year":"2019","journal-title":"Eur Respir J"},{"issue":"14","key":"10.1016\/j.hfc.2023.12.010_bib56","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/heartjnl-2015-307467","article-title":"The Fontan circulation after 45 years: Update in physiology","volume":"102","author":"Gewillig","year":"2016","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.hfc.2023.12.010_bib57","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1213\/ANE.0000000000000717","article-title":"Fontan physiology revisited","volume":"121","author":"Jolley","year":"2015","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.hfc.2023.12.010_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018790450","article-title":"The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials","volume":"9","author":"Wang","year":"2019","journal-title":"Pulm Circ"},{"issue":"2","key":"10.1016\/j.hfc.2023.12.010_bib59","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ehf2.12630","article-title":"Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design","volume":"7","author":"Amedro","year":"2020","journal-title":"ESC Hear Fail"},{"issue":"1","key":"10.1016\/j.hfc.2023.12.010_bib60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A\u00a0randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)","volume":"134","author":"Califf","year":"1997","journal-title":"Am Heart J"},{"issue":"21","key":"10.1016\/j.hfc.2023.12.010_bib61","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure: The heart failure ETA receptor blockade trial (HEAT)","volume":"106","author":"L\u00fcscher","year":"2002","journal-title":"Circulation"},{"issue":"9431","key":"10.1016\/j.hfc.2023.12.010_bib62","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","article-title":"Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): Randomised, double-blind, placebo-controlled trial","volume":"364","author":"Anand","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hfc.2023.12.010_bib63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000107791","article-title":"Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension\u2014A multi-center randomized study","volume":"109","author":"Kaluski","year":"2008","journal-title":"Cardiology"},{"issue":"2","key":"10.1016\/j.hfc.2023.12.010_bib64","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.hfc.2023.12.010_bib65","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"issue":"38","key":"10.1016\/j.hfc.2023.12.010_bib66","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: A randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.hfc.2023.12.010_bib67","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2023.12.010_bib68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cardfail.2007.11.006","article-title":"Effects of 5\u2032-Phosphodiesterase Four-Week Long Inhibition With Sildenafil in Patients With Chronic Heart Failure: A Double-Blind, Placebo-Controlled Clinical Trial","volume":"14","author":"Behling","year":"2008","journal-title":"J\u00a0Card Fail"},{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib69","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: A phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2023.12.010_bib70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ahj.2018.03.020","article-title":"The prevalence of pulmonary arterial hypertension before and after atrial septal defect closure at adult age: A systematic review","volume":"201","author":"Zwijnenburg","year":"2018","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.hfc.2023.12.010_bib71","first-page":"415","article-title":"An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease","volume":"13","author":"Ibrahim","year":"2006","journal-title":"Cancer Res J"},{"issue":"1","key":"10.1016\/j.hfc.2023.12.010_bib72","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2004.08.025","article-title":"Safety and tolerability of bosentan in adults with Eisenmenger physiology","volume":"98","author":"Gatzoulis","year":"2005","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2023.12.010_bib73","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1378\/chest.129.4.1009","article-title":"Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease","volume":"129","author":"Benza","year":"2006","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.hfc.2023.12.010_bib74","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1017\/S1047951106000114","article-title":"Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease","volume":"16","author":"Kotlyar","year":"2006","journal-title":"Cardiol Young"},{"issue":"4","key":"10.1016\/j.hfc.2023.12.010_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2005.07.005","article-title":"Adult patients with congenital heart disease and pulmonary arterial hypertension: First open prospective multicenter study of bosentan therapy","volume":"150","author":"Schulze-Neick","year":"2005","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib76","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1136\/hrt.2006.097360","article-title":"Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): Safety, tolerability, clinical, and haemodynamic effect","volume":"93","author":"D\u2019Alto","year":"2007","journal-title":"Heart"},{"issue":"8","key":"10.1016\/j.hfc.2023.12.010_bib77","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/hrt.2006.089185","article-title":"Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease","volume":"93","author":"Diller","year":"2007","journal-title":"Heart"},{"issue":"17","key":"10.1016\/j.hfc.2023.12.010_bib78","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.105.603001","article-title":"Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: A preliminary observational study","volume":"114","author":"Mukhopadhyay","year":"2006","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2023.12.010_bib79","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/clc.20917","article-title":"The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease","volume":"34","author":"Zeng","year":"2011","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.hfc.2023.12.010_bib80","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1536\/ihj.14-351","article-title":"Pulmonary arterial hypertension associated with tetralogy of Fallot","volume":"56","author":"Yasuhara","year":"2015","journal-title":"Int Heart J"},{"issue":"2","key":"10.1016\/j.hfc.2023.12.010_bib81","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00246-015-1278-2","article-title":"Use of Pulmonary Hypertension Medications in Patients with Tetralogy of Fallot with Pulmonary Atresia and Multiple Aortopulmonary Collaterals","volume":"37","author":"Grant","year":"2016","journal-title":"Pediatr Cardiol"},{"issue":"13","key":"10.1016\/j.hfc.2023.12.010_bib82","doi-asserted-by":"crossref","first-page":"827","DOI":"10.21037\/atm-20-1127","article-title":"Statistics of heart failure and mechanical circulatory support in 2020","volume":"8","author":"Bowen","year":"2020","journal-title":"Ann Transl Med"},{"issue":"11","key":"10.1016\/j.hfc.2023.12.010_bib83","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.healun.2013.06.024","article-title":"Organ allocation in adults with congenital heart disease listed for heart transplant: Impact of ventricular assist devices","volume":"32","author":"Gelow","year":"2013","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.hfc.2023.12.010_bib84","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacc.2016.05.082","article-title":"Wait-List Outcomes for Adults With Congenital Heart Disease Listed for Heart Transplantation in the U.S","volume":"68","author":"Alshawabkeh","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.hfc.2023.12.010_bib85","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.healun.2017.07.019","article-title":"The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report\u20142017; Focus Theme: Allograft ischemic time","volume":"36","author":"Lund","year":"2017","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.hfc.2023.12.010_bib86","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.healun.2010.09.008","article-title":"Would access to device therapies improve transplant outcomes for adults with congenital heart disease? Analysis of the United Network for Organ Sharing (UNOS)","volume":"30","author":"Everitt","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib87","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.healun.2017.11.010","article-title":"An Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of hospitalization, functional status, and mortality after mechanical circulatory support in adults with congenital heart disease","volume":"37","author":"Cedars","year":"2018","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"15","key":"10.1016\/j.hfc.2023.12.010_bib88","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/hrt.2009.184713","article-title":"Cardiac transplantation in adults with congenital heart disease","volume":"96","author":"Irving","year":"2010","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.hfc.2023.12.010_bib89","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.healun.2014.05.007","article-title":"Impact of adult congenital heart disease on survival and mortality after heart transplantation","volume":"33","author":"Burchill","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.hfc.2023.12.010_bib90","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.athoracsur.2009.04.071","article-title":"Heart Transplantation for Adults With Congenital Heart Disease: Analysis of the United Network for Organ Sharing Database","volume":"88","author":"Patel","year":"2009","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"10.1016\/j.hfc.2023.12.010_bib91","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.110.960260","article-title":"Listing and transplanting adults with congenital heart disease","volume":"123","author":"Davies","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2023.12.010_bib92","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.healun.2010.08.029","article-title":"Minimizing infection and rejection death: Clues acquired from 19 years of multi-institutional cardiac transplantation data","volume":"30","author":"George","year":"2011","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"11","key":"10.1016\/j.hfc.2023.12.010_bib93","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/TP.0b013e31823411d7","article-title":"Association between age and graft failure rates in young kidney transplant recipients","volume":"92","author":"Foster","year":"2011","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.hfc.2023.12.010_bib94","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jtcvs.2004.07.013","article-title":"Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure","volume":"128","author":"Mitchell","year":"2004","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"12","key":"10.1016\/j.hfc.2023.12.010_bib95","first-page":"1","article-title":"Hemodynamics of Fontan Failure: The Role of Pulmonary Vascular Disease","volume":"10","author":"Egbe","year":"2017","journal-title":"Circ Hear Fail"},{"issue":"1","key":"10.1016\/j.hfc.2023.12.010_bib96","doi-asserted-by":"crossref","first-page":"152","DOI":"10.21037\/acs.2018.01.16","article-title":"Transplantation in the single ventricle population","volume":"7","author":"Kenny","year":"2018","journal-title":"Ann Cardiothorac Surg"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713623001058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713623001058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:43:15Z","timestamp":1761554595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713623001058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1551713623001058"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2023.12.010","relation":{},"ISSN":["1551-7136"],"issn-type":[{"type":"print","value":"1551-7136"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Hypertension in Adult Congenital Heart Disease\u2013Related Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}